CD80, CD80 molecule, 941

N. diseases: 233; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE CD80 might be responsible for the breast cancer's progression and metastasis via regulating innate immune system. 30411299 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE We investigated whether in vitro WEE1 gene silencing in MDA-MB-468 and MCF7 breast cancer cell lines could enhance immunopotentiating effects of CD80 and 4-1BBL co-stimulation in human T cells. 26881506 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 GeneticVariation disease BEFREE The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined Pint≤2.7 × 10(-5)), one SNP in CD80 (combined Pint≤8.2 × 10(-6)), three SNPs on chr17 near TMEM132E (combined Pint≤2.2×10(-6)), and two SNPs on chr18 near SLC25A52 (combined Pint≤4.6 × 10(-5)). 24080446 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 AlteredExpression disease BEFREE We tested in Her2/neu+ breast cancer and HPV-16 E6/E7+ cervical cancer mouse models, whether intratumoral expression of immunostimulatory proteins (ISPs), for example, recombinant antibodies (αCTLA-4, αCD137, αCD3), cyto/chemokines (IL-15, LIGHT, mda-7) and costimulatory ligands (CD80), through adenovirus(Ad)-mediated gene transfer would overcome resistance. 21394107 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE Using CD80+ KS breast cancer cells and human leukocyte antigen (HLA)-A*02-matched peripheral blood mononuclear cells (PBMCs) of breast cancer patients in allogeneic mixed lymphocyte-tumor cell cultures (MLTCs), it was possible to isolate HLA-A*02-restricted cytotoxic T cells (CTLs). 15365776 2005
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE Synergy between interleukin-12 (IL-12) and B7-1 (CD80) for cancer immunotherapy has previously been demonstrated in animal models of breast cancer, lymphoma, and multiple myeloma. 11477456 2001
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 AlteredExpression disease BEFREE In long-term T-cell cultures, IL-12 synergizes with CD80 expression to stimulate cytolytic CD8+ T-cell lines, which recognize a breast carcinoma line in a human histocompatibility leukocyte antigen-restricted manner. 10359208 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE We used a human HLA-A2.1+ CD80-transfected breast carcinoma cell line (KS-CD80) and investigated in vitro the efficiency at which antigen (Ag)-specific responses were induced following the stimulation of allogeneic HLA-A2.1-matched T lymphocytes. 10359214 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.090 Biomarker disease BEFREE Cocultured with CD 80 transfected human breast carcinoma cell line MDA-453, anti-CD3 induced T cells proliferation and cytokine production were significantly increased in the presence of A23187 and PMA, but not with parental MDA-453. 10374432 1998